A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity

Human Molecular Genetics

Volumn 23, Issue 18, 2014, Pages 4887-4905

  Dusonchet, Julien ^a,b,c   Li, Hu ^d   Guillily, Maria ^a   Liu, Min ^e   Stafa, Klodjan ^f   Derada Troletti, Claudio ^a   Boon, Joon Y ^a   Saha, Shamol ^a   Glauser, Liliane ^f   Mamais, Adamantios ^g   Citro, Allison ^a   Youmans, Katherine L ^a   Liu, LiQun ^a   Schneider, Bernard L ^f   Aebischer, Patrick ^f   Yue, Zhenyu ^h   Bandopadhyay, Rina ^g   Glicksman, Marcie A ^e   Moore, Darren J ^f   Collins, James J ^b,c   Wolozin, Benjamin ^a   more..

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c Boston University   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f EPFL   (Switzerland)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LRRK2 PROTEIN, HUMAN; ONCOPROTEIN; PARK7 PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PTEN-INDUCED PUTATIVE KINASE; RGS PROTEIN; RGS2 PROTEIN, HUMAN; SIGNAL PEPTIDE; TRANSCRIPTOME;

ANIMAL; BLOOD; BRAIN; CAENORHABDITIS ELEGANS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; NERVE CELL; PARKINSON DISEASE; PATHOLOGY; PROCEDURES; SYSTEMS BIOLOGY;

ANIMALS; BRAIN; CAENORHABDITIS ELEGANS; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HEK293 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEURONS; ONCOGENE PROTEINS; PARKINSON DISEASE; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; RGS PROTEINS; SYSTEMS BIOLOGY; TRANSCRIPTOME;

EID: 84906836338     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu202     Document Type: Article

References (67)

1. Lesage, S., Durr, A., Tazir, M., Lohmann, E., Leutenegger, A.L., Janin, S., Pollak, P. and Brice, A. (2006) LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med., 354, 422-423.
2. Healy, D.G., Falchi, M., O'Sullivan, S.S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C.P., Goldwurm, S. et al. (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol., 7, 583-590.
3. Gasser, T. (2009) Mendelian forms of Parkinson's disease. Biochim. Biophys. Acta, 1792, 587-596.
4. Dusonchet, J., Kochubey, O., Stafa, K., Young, S.M. Jr, Zufferey, R., Moore, D.J., Schneider, B.L. and Aebischer, P. (2011) A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J. Neurosci., 31, 907-912.
5. Lee, B.D., Shin, J.H., VanKampen, J., Petrucelli, L., West, A.B., Ko, H.S., Lee, Y.I., Maguire-Zeiss, K.A., Bowers, W.J., Federoff, H.J. et al. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat. Med., 16, 998-1000.
6. West, A.B., Moore, D.J., Choi, C., Andrabi, S.A., Li, X., Dikeman, D., Biskup, S., Zhang, Z., Lim, K.L., Dawson, V.L. et al. (2007) Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet., 16, 223-232.
7. Imai, Y., Gehrke, S., Wang, H.-Q., Takahashi, R., Hasegawa, K., Ooata, E. and Lu, B. (2008) Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J., 27, 2432-2443.
8. Gillardon, F. (2009) Leucine-rich repeat kinase 2 phosphorylates brain tubulinbeta isoforms and modulates microtubule stability-a point of convergence in parkinsonian neurodegeneration? J. Neurochem., 110, 1514-1522.
9. Parisiadou, L., Xie, C., Cho, H.J., Lin, X., Gu, X.L., Long, C.X., Lobbestael, E., Baekelandt, V., Taymans, J.M., Sun, L. et al. (2009) Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci., 29, 13971-13980.
10. Stafa, K., Trancikova, A., Webber, P.J., Glauser, L., West, A.B. and Moore, D.J. (2012) GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet., 8, e1002526.
11. Xiong, Y., Yuan, C., Chen, R., Dawson, T.M. and Dawson, V.L. (2012) ArfGAP1is aGTPase activating protein forLRRK2:reciprocal regulation of ArfGAP1 by LRRK2. J. Neurosci., 32, 3877-3886.
12. Trancikova, A., Mamais, A., Webber, P.J., Stafa, K., Tsika, E., Glauser, L., West, A.B., Bandopadhyay, R. and Moore, D.J. (2012) Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. PLoS ONE, 7, e47784.
13. Kumar, A., Greggio, E., Beilina, A., Kaganovich, A., Chan, D., Taymans, J.M., Wolozin, B. and Cookson, M.R. (2010) The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS ONE, 5, e8730.
14. Lewis, P.A., Greggio, E., Beilina, A., Jain, S., Baker, A. and Cookson, M.R. (2007) The R1441C mutation of LRRK2disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun., 357, 668-671.
15. Daniels, V., Vancraenenbroeck, R., Law, B.M., Greggio, E., Lobbestael, E., Gao, F., De Maeyer, M., Cookson, M.R., Harvey, K., Baekelandt, V. et al. (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant. J. Neurochem., 116, 304-315.
16. Ito, G., Okai, T., Fujino, G., Takeda, K., Ichijo, H., Katada, T. and Iwatsubo, T. (2007)GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry, 6, 1380-1388.
17. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M.P., Beilina, A., Blackinton, J., Thomas, K.J. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis., 23, 329-341.
18. Li, X., Tan, Y.C., Poulose, S., Olanow, C.W., Huang, X.Y. and Yue, Z. (2007) Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem., 103, 238-247.
19. Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci., 9, 1231-1233.
20. Gehrke, S., Imai, Y., Sokol, N. and Lu, B. (2010) Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature, 466, 637-641.
21. Chan, D., Citro, A., Cordy, J.M., Shen, G.C. and Wolozin, B. (2011) Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J. Biol. Chem., 286, 16140-16149.
22. Piccoli, G., Condliffe, S.B., Bauer, M., Giesert, F., Boldt, K., De Astis, S., Meixner, A., Sarioglu, H., Vogt-Weisenhorn, D.M., Wurst, W. et al. (2011) LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J. Neurosci., 31, 2225-2237.
23. Saha, S., Guillily, M.D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., Hsu, C.H., Segal, L., Raghavan, K., Matsumoto, K. et al. (2009) LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci., 29, 9210-9218.
24. Plowey, E.D., Cherra, S.J., Liu, Y.-J. and Chu, C.T. (2008) Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem., 105, 1048-1056.
25. Gómez-Suaga, P., Luzón-Toro, B., Churamani, D., Zhang, L., Bloor-Young, D., Patel, S., Woodman, P.G., Churchill, G.C. and Hilfiker, S. (2011) Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum. Mol. Genet., 21, 511-525.
26. Tsika, E. and Moore, D.J. (2013) Contribution of GTPase activity to LRRK2-associated Parkinson disease. Small GTPases, 4, 164-170.
27. Rudenko, I.N., Chia, R. and Cookson, M.R. (2012) Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med., 10, 20.
28. Faith, J.J., Hayete, B., Thaden, J.T., Mogno, I., Wierzbowski, J., Cottarel, G., Kasif, S., Collins, J.J. and Gardner, T.S. (2007) Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles. PLoS Biol., 5, e8.
29. Moran, L.B., Duke, D.C., Deprez, M., Dexter, D.T., Pearce, R.K. and Graeber, M.B. (2006) Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics, 7, 1-11.
30. Scherzer, C.R., Eklund, A.C., Morse, L.J., Liao, Z., Locascio, J.J., Fefer, D., Schwarzschild, M.A., Schlossmacher, M.G., Hauser, M.A., Vance, J.M. et al. (2007) Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl Acad. Sci. USA, 104, 955-960.
31. Mutez, E., Larvor, L., Lepretre, F., Mouroux, V., Hamalek, D., Kerckaert, J.P., Perez-Tur, J., Waucquier, N., Vanbesien-Mailliot, C., Duflot, A. et al. (2011) Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation. Neurobiol. Aging, 32, 1839-1848.
32. Carballo-Carbajal, I., Weber-Endress, S., Rovelli, G., Chan, D., Wolozin, B., Klein, C.L., Patenge, N., Gasser, T. and Kahle, P.J. (2010) Leucine-rich repeat kinase 2 induces alpha-synuclein expression via the extracellular signal-regulated kinase pathway. Cell Signal., 22, 821-827.
33. Ho, C.C., Rideout, H.J., Ribe, E., Troy, C.M. and Dauer, W.T. (2009) The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J. Neurosci., 29, 1011-1016.
34. Hsu, C.H., Chan, D., Greggio, E., Saha, S., Guillily, M.D., Ferree, A., Raghavan, K., Shen, G.C., Segal, L., Ryu, H. et al. (2010) MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J. Neurochem., 12, 1593-1604.
35. Hsu, C.H., Chan, D. and Wolozin, B. (2010)LRRK2 and the stress response: interaction withMKKsand JNK-interacting proteins. Neurodegener. Dis., 7, 68-75.
36. Sancho, R.M., Law, B.M. and Harvey, K. (2009) Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum. Mol. Genet., 18, 3955-3968.
37. Venderova, K., Kabbach, G., Abdel-Messih, E., Zhang, Y., Parks, R.J., Imai, Y., Gehrke, S., Ngsee, J., Lavoie, M.J., Slack, R.S. et al. (2009) Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum. Mol. Genet., 18, 4390-4404.
38. Harrington, A.J., Knight, A.L., Caldwell, G.A. and Caldwell, K.A. (2011) Caenorhabditis elegans as a model system for identifying effectors of alpha-synuclein misfolding and dopaminergic cell death associated with Parkinson's disease. Methods, 53, 220-225.
39. Wolozin, B., Gabel, C., Ferree, A., Guillily, M. and Ebata, A. (2011) Watching Worms Whither Modeling Neurodegeneration in C. elegans. Prog. Mol. Biol. Transl. Sci., 100, 499-514.
40. Gloeckner, C.J., Schumacher, A., Boldt, K. and Ueffing, M. (2009) The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J Neurochem, 109, 959-968.
41. Liou, A.K., Leak, R.K., Li, L. and Zigmond, M.J. (2008) Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway. Neurobiol. Dis., 32, 116-124.
42. Rosen, E.Y., Wexler, E.M., Versano, R., Coppola, G., Gao, F., Winden, K.D., Oldham, M.C., Martens, L.H., Zhou, P., Farese, R.V. Jr. et al. (2011) Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. Neuron., 71, 1030-1042.
43. Aladzsity, I., Toth, M.L., Sigmond, T., Szabo, E., Bicsak, B., Barna, J., Regos, A., Orosz, L., Kovacs, A.L. and Vellai, T. (2007) Autophagy genes unc-51 and bec-1 are required for normal cell size in Caenorhabditis elegans. Genetics, 177, 655-660.
44. Furuya, N., Yu, J., Byfield, M., Pattingre, S. and Levine, B. (2005) The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function. Autophagy, 1, 46-52.
45. Larminie, C., Murdock, P., Walhin, J.P., Duckworth, M., Blumer, K.J., Scheideler, M.A. and Garnier, M. (2004) Selective expression of regulators of G-protein signaling (RGS) in the human central nervous system. Brain Res. Mol. Brain Res., 122, 24-34.
46. Stanwood, G.D., Parlaman, J.P. and Levitt, P. (2006) Genetic or pharmacological inactivation of the dopamine D1 receptor differentially alters the expression of regulator of G-protein signalling (Rgs) transcripts. Eur. J. Neurosci., 24, 806-818.
47. Dachsel, J.C., Behrouz, B., Yue, M., Beevers, J.E., Melrose, H.L. and Farrer, M.J. (2010) A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism Relat. Disord., 16, 650-655.
48. Bernstein, L.S., Ramineni, S., Hague, C., Cladman, W., Chidiac, P., Levey, A.I. and Hepler, J.R. (2004) RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11alpha signaling. J. Biol. Chem., 279, 21248-21256.
49. Bodenstein, J., Sunahara, R.K. and Neubig, R.R. (2007) N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells. Mol. Pharmacol., 71, 1040-1050.
50. Higashi, S., Biskup, S., West, A.B., Trinkaus, D., Dawson, V.L., Faull, R.L., Waldvogel, H.J., Arai, H., Dawson, T.M., Moore, D.J. et al. (2007) Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res., 1155, 208-219.
51. Biosa, A., Trancikova, A., Civiero, L., Glauser, L., Bubacco, L., Greggio, E. and Moore, D.J. (2013) GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2. Hum. Mol. Genet., 22, 1140-1156.
52. Sen, S., Webber, P.J. and West, A.B. (2009) Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J. Biol. Chem., 284, 36346-36356.
53. MacLeod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K. and Abeliovich, A. (2006) The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron, 52, 587-593.
54. Nichols, R.J., Dzamko, N., Hutti, J.E., Cantley, L.C., Deak, M., Moran, J., Bamborough, P., Reith, A.D. and Alessi, D.R. (2009) Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease. Biochem. J., 424, 47-60.
55. Beilina, A., Rudenko, I.N., Kaganovich, A., Civiero, L., Chau, H., Kalia, S.K., Kalia, L.V., Lobbestael, E., Chia, R., Ndukwe, K. et al. (2014) Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc. Natl Acad. Sci., USA, 111, 2626-2631.
56. Hollinger, S. and Hepler, J.R. (2002) Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. Pharmacol. Rev., 54, 527-559.
57. Taymans, J.M., Vancraenenbroek, R., Ollikainen, P., Beilina, A., Lobbestael, E., De Maeyer, M., Baekelandt, V. and Cookson, M.R. (2011) LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding. PLoS ONE, 6, e2320.
58. Cunningham, M.L., Waldo, G.L., Hollinger, S., Hepler, J.R. andHarden, T.K. (2001) Protein kinase C phosphorylates RGS2 and modulates its capacity for negative regulation of Galpha 11 signaling. J. Biol. Chem., 23, 5438-5444.
59. Taymans, J.M., Wintmolders, C., Te Riele, P., Jurzak, M., Groenewegen, H.J., Leysen, J.E. and Langlois, X. (2002) Detailed localization of regulator of G protein signaling 2 messenger ribonucleic acid and protein in the rat brain. Neuroscience, 114, 39-53.
60. Burchett, S.A., Bannon, M.J. and Granneman, J.G. (1999) RGS mRNA expression in rat striatum: modulation by dopamine receptors and effects of repeated amphetamine administration. J. Neurochem., 72, 1529-1533.
61. Robinet, E.A., Wurch, T. and Pauweis, P.J. (2001) Different regulation of RGS2 mRNA by haloperidol and clozapine. Neuroreport, 12, 1731-1735.
62. Taymans, J.M., Leysen, J.E. and Langlois, X. (2003) Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions. J. Neurochem., 84, 1118-1127.
63. Kimple, A.J., Bosch, D.E., Giguiere, P.M. and Siderovski, D.P. (2011) Regulators of G-protein signaling and their Ga substrates: promises and challenges in their use as drug discovery targets. Pharmacol. Rev., 63, 728-749.
64. Langer, I., Tikhonova, I.G., Boulegue, C., Esteve, J.P., Vatinel, S., Ferrand, A., Moroder, L., Robberecht, P. and Fourmy, D. (2009) Evidence for a direct and functional interaction between the regulators of G protein signaling-2 and phosphorylated C-terminus of cholecystokinin-2 receptor. Mol. Pharm., 75, 502-513.
65. di Bernardo, D., Thompson, M.J., Gardner, T.S., Chobot, S.E., Eastwood, E.L., Wojtovich, A.P., Elliott, S.J., Schaus, S.E. and Collins, J.J. (2005) Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. Nat. Biotechnol., 23, 377-383.
66. Sarbassov, D.D., Guertin, D.A., Ali, S.M. and Sabatini, D.M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 307, 1098-1101.
67. Deglon, N., Tseng, J.L., Bensadoun, J.C., Zurn, A.D., Arsenijevic, Y., Pereira de Almeida, L., Zufferey, R., Trono, D. and Aebischer, P. (2000) Self-inactivating lentiviral vectors with enhanced transgene expression as potential gene transfer system in Parkinson's disease. Hum. Gene Ther., 11, 179-190.